Active, not recruitingPhase 3NCT05693129
Pediatric Patients Aged 1 to 6 Years With APDS
Studying Activated PI3K-delta syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pharming Technologies B.V.
- Intervention
- Leniolisib(drug)
- Enrollment
- 16 enrolled
- Eligibility
- 1-6 years · All sexes
- Timeline
- 2023 – 2026
Study locations (9)
- University of California Los Angeles, Los Angeles, California, United States
- National Institutes of Health, Bethesda, Maryland, United States
- Rainbow Childrens Hospital, Shaker Heights, Ohio, United States
- Texas Children's Hospital, Houston, Texas, United States
- Kyoto University Hospital, Kyoto, Japan
- Institute of Science Tokyo Hospital, Tokyo, Japan
- Hospital Pediátrico de Coimbra da ULS Coimbra UNIDADE LOCAL DE SAÚDE DE COIMBRA, Coimbra, Portugal
- Hospital Universitario Virgen del Rocío, Seville, Spain
- Great Ormond Street Hospital, London, United Kingdom
Collaborators
CMIC Co, Ltd. Japan · Labcorp Central Laboratory · Fortrea · Aixial Group
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05693129 on ClinicalTrials.govOther trials for Activated PI3K-delta syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06694363New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ SyndromeAssistance Publique - Hôpitaux de Paris
- ACTIVE NOT RECRUITINGPHASE3NCT05438407Pediatric Patients Aged 4 to 11 Years With APDSPharming Technologies B.V.
- RECRUITINGNCT06566872Collecting Recorded Videos of Colonoscopy and Gastroscopy Tests for the Evaluation of the (ME-APDS).Magentiq Eye LTD